Golden
Aclaris Therapeutics

Aclaris Therapeutics

Aclaris Therapeutics is a company developing treatments for dermatology and immunology.

All edits

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:20 pm
Edits made to:
Infobox (+1 properties)
Edits on 30 Apr 2019
Liron Shapira
Liron Shapira approved a suggestion from Golden's AI on 30 Apr 2019 9:13 pm
Edits made to:
Article (+8/-8 characters)

Article

Aclaris has two commercialized products in its portfolio, Eskata and Rhofade. Eskata is topical treatment for SKs (seborrheic keratoses). SKs are harmless spots that pop up as a person ages. Rhofade on the other hand, is a topical treatment for persistent facial erythema associated with rosacea in adults. Rhofade was originally developed by AllerganAllergan, which Aclaris then acquired the worldwide rights to.

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 6:46 pm
Edits made to:
Infobox (+5/-1 properties)
Timeline (+3 events) (+762 characters)
Article (+844/-26 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Aclaris Therapeutics is a publicly held biopharmaceutical company basedheadquartered in that Waynewas founded in 2012 by Christopher Powala, , PennsylvaniaFrank Ruffo, Neal Walker, Stuart D. Shanler. itIt focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.



Products

...



Funding

Series A

On October 24, 2012 Aclaris Therapeutics completed their series A funding round with $21 million in funding from Vivo Capital (lead investor), F-Prime Capital Partners (lead investor), and Sofinnova Ventures. 

Series B

On October 2, 2014 Aclaris Therapeutics completed their series B funding round with $21million in funding from Vivo Capital, F-Prime Capital Partners, and Sofinnova Ventures.

Series C

On September 9, 2015 Aclaris Therapeutics completed their series C funding round with $40 million in funding from RA Capital Management (lead investor), Vivo Capital, Sofinnova Ventures, Rock Springs Capital, Mossrock Capital, F-Prime Capital Partners, Cormorant Asset Management, and Aperture Venture Partners. 

Infobox

Categories

Related Topics

Timeline

September 9, 2015

Series C funding round

On September 9, 2015 Aclaris Therapeutics completed their series C funding round with $40 million in funding from RA Capital Management (lead investor), Vivo Capital, Sofinnova Ventures, Rock Springs Capital, Mossrock Capital, F-Prime Capital Partners, Cormorant Asset Management, and Aperture Venture Partners. 

October 2, 2014

Series B funding round

On October 2, 2014 Aclaris Therapeutics completed their series B funding round with $21million in funding from Vivo Capital, F-Prime Capital Partners, and Sofinnova Ventures.

October 24, 2012

Series A funding round

On October 24, 2012 Aclaris Therapeutics completed their series A funding round with $21 million in funding from Vivo Capital (lead investor), F-Prime Capital Partners (lead investor), and Sofinnova Ventures. 

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:15 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 11 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Jan 2019 3:47 pm
Edits made to:
Article (+19/-19 characters)

Article

Aclaris Therapeutics is a publicly held biopharmaceutical company based in Wayne, PennsylvaniaWayne, Pennsylvania. it focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.

Lena Kourkouta
Lena Kourkouta approved a suggestion from Golden's AI on 11 Jan 2019 3:45 pm
Edits made to:
Article (+15/-15 characters)

Article

ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areataalopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.

Sameeha Sulaiman
Sameeha Sulaiman edited on 11 Jan 2019 12:32 pm
Edits made to:
Infobox (+3/-3 properties)
Description (+10/-9 characters)
Article (+2295 characters)
People (+8 rows) (+16 cells) (+374 characters)
Further reading (+1 rows) (+4 cells) (+245 characters)
Topic thumbnail

Aclaris Therapeutics

A company dvelopingdeveloping treatments for dermatology and immunology.

Article

Aclaris Therapeutics is a publicly held biopharmaceutical company based in Wayne, Pennsylvania. it focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.



Aclaris has two commercialized products in its portfolio, Eskata and Rhofade. Eskata is topical treatment for SKs (seborrheic keratoses). SKs are harmless spots that pop up as a person ages. Rhofade on the other hand, is a topical treatment for persistent facial erythema associated with rosacea in adults. Rhofade was originally developed by Allergan, which Aclaris then acquired the worldwide rights to.



The company also has several other product candidates in its pipeline at various stages of development. A-101 is a topical solution for the treatment of common warts that will be entering Phase 3 of clinical trials. 



ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.



ATI-501 is an oral JAK1/JAK3 inhibitor under investigation for the more severe forms of alopecia areata, alopecia totalis and alopecia universalis. An IND was filed in 2016 for this product. ATI-501 is a pro-drug that is converted to its active form, ATI-502.

...

Other product candidates in Phase 1 and pre-clinical stages are:

  • ATI-450MK2 pathway inhibitor - oral form is being investigated as a potential treatment for rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated period syndroms, and pyoderma gangrenosum.
  • ATI-1777JAK1/JAK3 inhibitor - soft topical form is being investigated as a potential treatment for atopic dermatitis, vitiligo, and alopecia areata.
  • ITK/JAK3 inhibitor - soft topical and oral forms being investigated for potential in treating psoriasis, inflammatory dermatoses, and inflammatory bowel disease.
  • MK2 pathway inhibitor - oral forms being investigated for potential in oncology.



People

Name
Role
Related Golden topics

Brett Fair

Chief Commercial Officer



Christopher Powala

Chief Regulatory and Development Officer



Dr. David Gordon

Chief Medical Officer



Dr. Neal Walker

President, Director, & CEO



Frank Ruffo

CFO & Treasurer



Joseph Monahan

Executive VP, Research and Development



Kamil Ali-Jackson

Chief Legal Officer, Chief Compliance Officer, & Corporate Secretary



Stuart D. Shanler

Chief Scientific Officer



Further reading

Title
Author
Link
Type

Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan

Aclaris Therapeutics, Inc.

Web

Infobox

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 9:44 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:06 am
Edits made to:
Infobox (+3 properties)
Edits on 14 Nov 2018
Jude Gomila"Approved suggestion from source: http://www.aclaristx.com"
Jude Gomila approved a suggestion from Golden's AI on 14 Nov 2018 3:16 am
Edits made to:
Infobox (+1 properties)
Edits on 9 Nov 2018
Jude Gomila"Approved suggestion from source: http://www.aclaristx.com"
Jude Gomila approved a suggestion from Golden's AI on 9 Nov 2018 11:42 pm
Edits made to:
Infobox (+1 properties)
Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 7:58 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:52 pm

Infobox

Location
Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:42 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:51 pm
Edits made to:
Description (+62/-21 characters)
Topic thumbnail

Aclaris Therapeutics

Biotechnology company

A company dveloping treatments for dermatology and immunology.

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:33 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Aclaris Therapeutics

Biotechnology company

Categories

No more activity to show.